—
Aryzta: Mysterious buyer from the board of directors is picking up again. Buys shares with a market value of 1.8 million CHF. More on the subject at 12.30 pm in my column.
Temenos: The stock lit a price fireworks yesterday in late trading. Accompanied by conspicuous purchases in the call warrants TEMNJB and TEMLJB. Allegedly the financial investor is courting EQT for the favor of the Geneva banking software company. ADRs in New York + 20pc. However, ZKB only remains for MARKET WEIGHTS.
Achiko: Reports first sales order for Covid-19 diagnostic test AptameX.
Arbonia: Kepler Cheuvreux goes on HOLD (Buy) to 22 (21) Fr. The crap seems to be out. Vontobel is already for HOLD. Recently, however, up to 17 (16) Fr.
Bossard: Pleasing preliminary information on today’s Investor Day. Unsurprisingly, raises the medium-term targets. Vontobel stays for HOLD up to CHF 325.
Datwyler: Achieves a profit of CHF 58 million on the Reichelt sale.
Idorsia: Goldman Sachs lowers CHF 17.50 (18.50) with NEUTRAL. JP Morgan is also for NEUTRAL. However up to 21 (29) Fr.
Logitech: Goldman Sachs is for NEUTRAL up to 102 (118) Fr., Credit Suisse for OUTPERFORM up to 114 (139) Fr., JP Morgan for OVERWEIGHT up to 111 (130) $ and Morgan Stanley for UNDERWEIGHT up to 77 (80) $. There is something for every taste.
Novartis: US health authority FDA wants to accelerate the examination of application supplements for gene therapy Kymriah with a “priority review”. JP Morgan cuts to 80 (84) Fr. with UNDERWEIGHT. Long-term growth prospects rather mild.
Phoenix Mecano: Research Partners go BUY (Hold) to $ 535. Reports progress in passing higher commodity prices on to customers.
Relief Therapeutics: Has come up with positive study results for Sentinox.
Roche: Enspryng receives the so-called “Orphan Drug Designation” from the US FDA. Positive.
Schindler: Research Partners cut to CHF 270 (290) with HOLD. Sees gloomy clouds on the horizon. Julius Baer reduces to CHF 250 (295), also with HOLD.
SIG Combibloc: Credit Suisse reduced to CHF 24 (25.30) with NEUTRAL.
Scan: Issue price of CHF 54 per share at the very upper end of the price range of CHF 44 to 55. Implied market value of CHF 1.2 billion.
Sulzer: Incoming orders first nine months CHF 2.35 billion (exp. CHF 2.33 billion). Outlook “only” confirmed. Could make for one or the other disappointed face. Vontobel stays for HOLD up to CHF 94.
UBS: DZ Bank goes to HOLD (buy) until 18 Fr., Bank of America is for BUY until 6.40 (17.40) Fr., Credit Suisse for OUTPERFORM until 19.50 (18.50) Fr., Berenberg Bank for BUY until 18.50 (17.50) Fr. ., Citigroup for BUY up to 22 (21) Fr., Royal Bank of Canada for OUTPERFORM up to 20 (19) Fr., Morgan Stanley for OVERWEIGHT up to 20 (17) Fr., HSBC for BUY up to 18 (17.20) Fr., Kepler Cheuvreux for BUY up to 21 (20) Fr., Deutsche Bank for BUY up to 19 (18) Fr., Vontobel also for BUY up to 18.50 (17) Fr. and Barclays for UNDERWEIGHT up to 16.50 (15) Fr. Target price adjustments.
Vifor: Reports disappointing results for ANG-3777 in transplant patients. Vontobel cuts it to CHF 126 (128) with HOLD. Kepler Cheuvreux is also available for HOLD up to CHF 126.
V-train: Martin Buhofer cashes in. Reduced share package to under 3pc.
Derivatives: Conspicuous sales in the call warrant SUNCJB on Sulzer as well as in the knock-out put SDACGV on the DAX.
–
